Andreas Wunder
Overview
Explore the profile of Andreas Wunder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
568
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meiering M, Weigner D, Gartner M, Carstens L, Keicher C, Hertrampf R, et al.
Transl Psychiatry
. 2024 Dec;
14(1):483.
PMID: 39632823
No abstract available.
2.
Meiering M, Weigner D, Gartner M, Carstens L, Keicher C, Hertrampf R, et al.
Transl Psychiatry
. 2024 Oct;
14(1):436.
PMID: 39402015
Ketamine is a highly effective antidepressant (AD) that targets the glutamatergic system and exerts profound effects on brain circuits during negative emotional processing. Interestingly, the effects of ketamine on brain...
3.
Grimm S, Just S, Fuertig R, Dwyer J, Sharma V, Wunder A
Eur Arch Psychiatry Clin Neurosci
. 2024 Sep;
PMID: 39343822
Transient receptor potential canonical (TRPC) ion channels are expressed in areas of the brain responsible for processing emotion and mood and have been implicated in the pathophysiology of internalizing disorders...
4.
Gartner M, Weigand A, Meiering M, Weigner D, Carstens L, Keicher C, et al.
Transl Psychiatry
. 2024 Jun;
14(1):258.
PMID: 38890270
Neuroimaging studies have identified the anterior cingulate cortex (ACC) as one of the major targets of ketamine in the human brain, which may be related to ketamine's antidepressant (AD) mechanisms...
5.
Eertink J, Bahce I, Waterton J, Huisman M, Boellaard R, Wunder A, et al.
Front Med (Lausanne)
. 2024 May;
11:1347267.
PMID: 38818386
Immune-based treatment approaches are successfully used for the treatment of patients with cancer. While such therapies can be highly effective, many patients fail to benefit. To provide optimal therapy choices...
6.
Preller K, Scholpp J, Wunder A, Rosenbrock H
Biol Psychiatry
. 2024 Jan;
96(8):666-673.
PMID: 38272287
Schizophrenia is a chronic mental illness that affects up to 1% of the population. While efficacious therapies are available for positive symptoms, effective treatment of cognitive and negative symptoms remains...
7.
Goettel M, Fuertig R, Mack S, Just S, Sharma V, Wunder A, et al.
CNS Drugs
. 2023 Nov;
37(12):1099-1109.
PMID: 38019356
Introduction: Depression, anxiety, and/or panic disorder are often comorbid and have a complex etiology mediated through the same neuronal network. Cholecystokinin-tetrapeptide (CCK-4), a synthetic analog of the endogenous neuropeptide cholecystokinin...
8.
Carstens L, Popp M, Keicher C, Hertrampf R, Weigner D, Meiering M, et al.
Trials
. 2023 Nov;
24(1):761.
PMID: 38012795
Background: Anhedonia and other deficits in reward- and motivation-related processing in psychiatric patients, including patients with major depressive disorder (MDD), represent a high unmet medical need. Neurobiologically, these deficits in...
9.
Region- and time- specific effects of ketamine on cerebral blood flow: a randomized controlled trial
Gartner M, Weigand A, Meiering M, Weigner D, Carstens L, Keicher C, et al.
Neuropsychopharmacology
. 2023 May;
48(12):1735-1741.
PMID: 37231079
There is intriguing evidence suggesting that ketamine might have distinct acute and delayed neurofunctional effects, as its acute administration transiently induces schizophrenia-like symptoms, while antidepressant effects slowly emerge and are...
10.
Signore A, Bonfiglio R, Varani M, Galli F, Campagna G, Desco M, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986677
Imaging using radiolabelled monoclonal antibodies can provide, non-invasively, molecular information which allows for the planning of the best treatment and for monitoring the therapeutic response in cancer, as well as...